Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Other Accumulated Expenses (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Other Accumulated Expenses for 2 consecutive years, with $2000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 99.57% to $2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Dec 2025, down 99.57% year-over-year, with the annual reading at $2000.0 for FY2025, 99.57% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $2000.0 at NRX Pharmaceuticals, down from $98000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $992000.0 in Q1 2024, with the low at $2000.0 in Q4 2025.